MTAP and esophageal cancer: Methylthioadenosine phosphorylase (MTAP)-deficient tumors account for ~15% of solid tumors, including ~15% of NSCLC, 28% of esophageal cancer, 26% of bladder cancer, and 10% of esophagogastric cancer.